CN100580447C - Method for determining human plasma antiviral drug concentration - Google Patents
Method for determining human plasma antiviral drug concentration Download PDFInfo
- Publication number
- CN100580447C CN100580447C CN200710044448A CN200710044448A CN100580447C CN 100580447 C CN100580447 C CN 100580447C CN 200710044448 A CN200710044448 A CN 200710044448A CN 200710044448 A CN200710044448 A CN 200710044448A CN 100580447 C CN100580447 C CN 100580447C
- Authority
- CN
- China
- Prior art keywords
- penciclovir
- ganciclovir
- acyclovir
- concentration
- tfa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Abstract
The invention belongs to medical detection field, relates to an analysis detection method of drug in the body of a person, and specifically relates to the method that the densities of antiviral drugs in blood plasma of the person such as acyclovir, ganciclovir and penciclovir can be detected at the same time. The method in the invention is characterized in that pilot sample is pretreated; as acyclovir, ganciclovir and penciclovir have the character of strong fluorescence absorption, acyclovir, ganciclovir and penciclovir can be separated from each other in an acidity flowing phase chromatographic column and be detected by a fluorescence detector. The method in the invention has the advantages of little sample, simple, swift and sensitive pretreatment, short analysis period and low cost; furthermore, the invention doesn't need expensive equipment and reagent and is suitable for the detection of clinical conventional blood drug density of acyclovir, ganciclovir and penciclovir.
Description
Technical field
The invention belongs to field of medical examination, relate to the analysis determining method of drug disposition, be specifically related to a kind of method of measuring antiviral drug concentration in the human plasma.
Background technology
At present, the clinical antiviral drugs that is used for the treatment of viral disease is some, and Acyclovir (Acyclovir, ACV), Ganciclovir (Ganciclovir, GCV) and Penciclovir (Penciclovir PCV) is ucleosides antiviral drugs at present commonly used clinically.Wherein ACV and GCV are most important anti-cytomegalovirus medicines.PCV mainly has potent inhibiting effect to I, II herpes simplex virus type, varicellazoster virus and hepatitis type B virus etc.When PCV and ACV or GCV share, clinical efficacy obviously strengthens.Because the pharmacokinetics interindividual variation of three kinds of medicines is big, drug combination is general, hepatic and renal function can cause drug plasma concentration and pharmacodynamic change unusually; therefore adjust dosage by the concentration that detects said medicine in the blood plasma, to the safety that guarantees medication with the important clinical meaning is effectively arranged.
At present in the medical test, the domestic report that the method for measuring in the human plasma relevant antiviral drug concentration is respectively arranged, but many disadvantages such as sensitivity is low, complex operation is time-consuming, efficient is low, analysis cost height that described method exists are not suitable for the conventional therapy monitor drug concentration; External do not see the report of measuring the concentration of ACV, GCV and PCV in the human plasma relevant the time as yet.
Summary of the invention
The objective of the invention is to overcome the defective of prior art, provide a kind of easy, quick, sensitive, can measure Acyclovir (Acyclovir in the body simultaneously, ACV), Ganciclovir (Ganciclovir, GCV) and Penciclovir (Penciclovir, the method for blood concentration PCV).
This method need not expensive equipment and reagent, has easy and simple to handle, quick, few, the low cost and other advantages of blood plasma consumption, is fit to conventional therapeutic drug monitoring.
The technical scheme of the inventive method is: after the testing sample pre-service, separate in chromatographic column through acid moving phase, detect with fluorescence detector, comprise the steps:
1) sample pretreatment
Get testing sample, add quantitative protein precipitant carry out albumen precipitation, centrifugal, get the supernatant sample introduction, described protein precipitant is 7～20% perchloric acid solution;
2) sample separation
Adopt universal liquid-phase chromatographic column, its filler is Diamonsil C
18, the high performance liquid chromatogram system adopts universal high-pressure pump and injector, and the mixed liquor that adopts 0.08～0.1% trifluoroacetic acid (TFA) aqueous solution (pH=2.1～2.5) and methyl alcohol is as moving phase, gradient elution;
Preferred 0～the 7min of gradient elution mode is 0.08～0.1%TFA aqueous solution-methyl alcohol (96: 4, V/V), 7.01～10.0min be 0.08～0.1%TFA aqueous solution-methyl alcohol (40: 60, V/V), 10.01～12.5min be 0.08～0.1%TFA aqueous solution-methyl alcohol (96: 4, V/V);
3) sample detection
Adopt universal fluorescence detector to detect the peak area of ACV, GCV and PCV, fluorescence exciting wavelength is 260 ± 1nm, and emission wavelength is 380 ± 1nm, is converted into concentration with the typical curve equation.
This method has the following advantages:
1. sampling quantity is few: measure a duplicate samples and only need the 0.2ml plasma sample;
2. pre-service is easy: a step perchloric acid solution albumen precipitation, and simple and easy to do, be applicable to conventional sense;
3. highly sensitive: have the characteristic that hyperfluorescence absorbs according to ACV, GCV and PCV under acid condition, adopt acid moving phase and fluoroscopic examination, obviously improve detection sensitivity, the minimum quantitative limit of ACV, GCV and PCV is 20 μ gL
-1, significantly be better than the disclosed GCV 100 μ gL of prior art
-1, ACV100 μ gL
-140 μ gL with PCV
-1
Minute is short: whole stratographic analysis mensuration process is 12.5min.
The described ACV of this method, GCV and PCV setting-out line scope are 20～2000 μ gL
-1, the method recovery is all greater than 91%, in a few days and precision in the daytime (relative standard deviation is RSD) all less than 8%.The inventive method quick and precisely, easy and simple to handle, highly sensitive, cost is low, is fit to routine clinical monitoring.
Description of drawings
Fig. 1: typical color spectrogram:
Wherein, A: the blank plasma of not taking Acyclovir, Ganciclovir and Penciclovir experimenter; B: (Acyclovir, Ganciclovir and Penciclovir three's concentration is 20 μ gL for blank plasma+Acyclovir, Ganciclovir and Penciclovir standard items
-1);
1: interior mark (guanylic acid); 2: Ganciclovir; 3: Acyclovir; 4: Penciclovir.
Fig. 2: take Acyclovir, Ganciclovir and Penciclovir experimenter's chromatogram,
Wherein, 1: interior mark (guanylic acid); 2: (concentration is 692.6 μ gL to Ganciclovir
-1); 3: (concentration is 760.3 μ gL to Acyclovir
-1); 4: (concentration is 910.5 μ gL to Penciclovir
-1).
Fig. 3 for the experimenter takes described three kinds antiviral,
Fig. 3: take the analysis chromatogram of the experimenter behind Acyclovir, Ganciclovir and the Penciclovir medicine simultaneously,
Wherein, 1: interior mark (guanylic acid); 2: (concentration is 692.6 μ gL to Ganciclovir
-1); 3: (concentration is 760.3 μ gL to Acyclovir
-1); 4: (concentration is 910.5 μ gL to Penciclovir
-1).
Embodiment
Chromatographic condition:
HPLC system: chromatographic column Diamonsil C
18(200mm * 4.6mm, 5 μ m), moving phase adopts gradient elution, and 0～7min is 0.08%TFA-methyl alcohol (96: 4, V/V), 7.01～10.0min be 0.08%TFA-methyl alcohol (40: 60, V/V), 10.01～12.5min be 0.08%TFA-methyl alcohol (96: 4, V/V), flow velocity 1.5mLmin
-125 ℃ of column temperatures; Fluorescence exciting wavelength 260 ± 1nm, emission wavelength 380 ± 1nm.
The plasma sample pre-service:
The accurate 200 μ L blood plasma of drawing are put in the 1.5mL centrifuge tube, add 7% perchloric acid solution, the 50 μ L of mark guanylic acid in containing, and 30s is extracted in the vortex vibration, and centrifugal 15min (10000 * g, 4 ℃) gets supernatant 40 μ L sample introductions, and internal standard method is with peak area quantification.
Specificity:
Get 10 blank plasmas of not taking the experimenter of ACV, GCV and PCV of separate sources, measure according to above-mentioned sample pretreatment and assay method, the result shows, does not find that the blood plasma endogenous material has interference to the said determination component; In addition, common drug combination valganciclovir, Valaciclovir, Ganciclovir, Penciclovir, Ribavirin, acemetacin, Indomethacin, atenolol, metoprolol, Propranolol, cyclosporine, tacrolimus, sirolimus, prednisone, mizoribine, Mycophenolic Acid, aspirin, paracetamol etc. do not disturb measuring.In the typical chromatographic retention of mark guanylic acid, ACV, GCV and PCV be respectively 3.9,6.8,5.1 and 7.8min, whole stratographic analysis process time is 12.5min.
Linear test:
Precision takes by weighing ACV, GCV and the PCV standard substance is an amount of, uses 50% dissolve with methanol, is diluted to serial working fluid, adds an amount of blank human plasma again, is mixed with to contain ACV 20,100,500,1000,1500,2000 μ gL
-1, GCV 20,100,500,1000,1500,2000 μ gL
-1With PCV 20,100,500,1000,1500,2000 μ gL
-1The standard blood sample.Get blood plasma 200 μ L, by " the plasma sample pre-service " the method operation.Internal standard method is made weighting (1/C with component to be measured and interior target peak area ratio (A) and concentration of component to be measured (C)
2) linear regression, the range of linearity is 20～2000 μ gL
-1, minimum quantitative limit is 20 μ gL
-1, three's typical curve regression equation is respectively: ACV A=0.00117C-0.00373, r=0.9996; GCVA=0.00135 C-0.000682, r=0.9997; PCV A=0.00345 C-0.0117, r=0.9996.
Accuracy and precision:
Precision takes by weighing ACV, GCV and the PCV standard substance is an amount of, and 50% dissolve with methanol also is diluted to serial working fluid, adds an amount of blank human plasma again, is mixed with to contain ACV40,800,1600 μ gL
-1, GCV40,800,1600 μ gL
-1With PCV 40,800,1600 μ gL
-1Serial blood sample, respectively get blood plasma 200 μ L, by " the plasma sample pre-service " method operation, investigate in a few days and precision in the daytime and accuracy.Calculate its measured concentration according to equation of linear regression, calculate actual measurement mean value, deviation and the relative standard deviation (RSD) of every kind of concentration, wherein (C
Actual measurement-C
Theoretical)/C
Theoretical* 100% is deviation.The result show three kinds of determinands in a few days with day to day precision all less than 8%, relative deviation is less than 10%.
Table 1 shown ACV, GCV and PCV in a few days, day to day precision and accuracy.
This method is used for taking simultaneously Acyclovir, Ganciclovir and Penciclovir experimenter's mensuration, and the result shows that Acyclovir, Ganciclovir and Penciclovir three's concentration is respectively 692.6,760.3 and 910.5 μ gL
-1
Embodiment 2:
Chromatographic condition:
HPLC system: chromatographic column Diamonsil C
18(200mm * 4.6mm, 5 μ m), moving phase adopts gradient elution, and 0～7min is 0.1%TFA-methyl alcohol (96: 4, V/V), 7.01～10.0min be 0.1%TFA-methyl alcohol (40: 60, V/V), 10.01～12.5min be 0.1%TFA-methyl alcohol (96: 4, V/V), flow velocity 1.5mLmin
-125 ℃ of column temperatures; Fluorescence exciting wavelength 260 ± 1nm, emission wavelength 380 ± 1nm.
The plasma sample pre-service:
The accurate 200 μ L blood plasma of drawing are put in the 1.5mL centrifuge tube, add 20% perchloric acid solution, the 25 μ L of mark guanylic acid in containing, vortex vibration 30s, and centrifugal 10min (12000 * g, 4 ℃) gets supernatant 40 μ L sample introductions, and internal standard method is with peak area quantification.
Specificity:
Get 10 blank plasmas of not taking the experimenter of ACV, GCV and PCV of separate sources, measure, do not find that the blood plasma endogenous material has interference to the said determination component according to above-mentioned sample pretreatment and assay method.In addition, common drug combination, immunodepressant and non-prescribed medicine (medicine described in the embodiment 1) are not disturbed measuring.In the retention time of mark guanylic acid, ACV, GCV and PCV be respectively 3.9,6.8,5.1 and 7.8min.
Linear test:
Precision takes by weighing ACV, GCV and the PCV standard substance is an amount of, uses 50% dissolve with methanol, is diluted to serial working fluid, adds an amount of blank human plasma again, is mixed with to contain ACV 20,100,500,1000,1500,2000 μ gL
-1, GCV 20,100,500,1000,1500,2000 μ gL
-1With PCV 20,100,500,1000,1500,2000 μ gL
-1The standard blood sample.Get blood plasma 200 μ L, by " the plasma sample pre-service " the method operation.Internal standard method is made weighting (1/C with component to be measured and interior target peak area ratio (A) and concentration of component to be measured (C)
2Linear regression, three's the range of linearity are 20～2000 μ gL
-1, minimum quantitative limit is 20 μ gL
-1, three's typical curve regression equation is respectively: ACV A=0.00121C-0.0033, r=0.9995; GCVA=0.00133C-0.00071, r=0.9997, r=0.9997; PCV A=0.00315C-0.0087, r=0.9991.
Accuracy and precision:
Precision takes by weighing ACV, GCV and the PCV standard substance is an amount of, and 50% dissolve with methanol also is diluted to serial working fluid, adds an amount of blank human plasma again, makes to contain ACV40,800,1600 μ gL
-1, GCV40,800,1600 μ gL
-1With PCV 40,800,1600 μ gL
-1Serial blood sample, respectively get blood plasma 200 μ L, by " the plasma sample pre-service " method operation, investigate in a few days and precision in the daytime and accuracy.Calculate its measured concentration according to equation of linear regression, calculate actual measurement mean value, deviation and the relative standard deviation (RSD) of every kind of concentration, wherein (C
Actual measurement-C
Theoretical)/C
Theoretical* 100% is deviation.The result show three kinds of medicines precision and relative deviation be all less than 11% in a few days, in the daytime.
Table 2 shown three kinds of medicines in a few days, day to day precision and accuracy.
Table 1
Table 2
Claims (2)
1, a kind of method of measuring antiviral drug concentration in the human plasma, it is characterized in that the testing sample pre-service after, under acid moving phase, after chromatographic column is separated, detect with fluorescence detector, may further comprise the steps:
1) sample pretreatment
Measure plasma concentration: get testing sample, add 7～20% perchloric acid solutions, carry out albumen precipitation, centrifugal after, get the supernatant sample introduction;
2) sample separation
Adopt universal liquid-phase chromatographic column, its filler is Dikma Diamonsil C
18, the high performance liquid chromatogram system adopts universal fluorescence detector and high-pressure pump, and moving phase is acid, gradient elution;
3) fluorescence detector detects
Fluorescence exciting wavelength 260 ± 1nm, emission wavelength 380 ± 1nm measures peak area, is converted into concentration with the typical curve equation;
Antiviral drugs is Acyclovir, Ganciclovir and Penciclovir in the described human plasma.
2, the method for antiviral drug concentration in the mensuration human plasma according to claim 1 is characterized in that described step 2) in chromatographic condition be chromatographic column adopting Dikma Diamonsil C
18: 200mm * 4.6mm, 5 μ m; Column temperature: 25 ℃, moving phase is acid moving phase: 0.08～0.1% trifluoroacetic acid (TFA)-methyl alcohol mixed liquor, gradient elution: its condition is that 0～7min is 0.08～0.1%TFA-methyl alcohol 96: 4, V/V, 7.01～10.0min is 0.08～0.1%TFA-methyl alcohol 40: 60, V/V, 10.01～12.5min are 0.08～0.1%TFA-methyl alcohol 96: 4, V/V.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710044448A CN100580447C (en) | 2007-07-31 | 2007-07-31 | Method for determining human plasma antiviral drug concentration |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710044448A CN100580447C (en) | 2007-07-31 | 2007-07-31 | Method for determining human plasma antiviral drug concentration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101105478A CN101105478A (en) | 2008-01-16 |
| CN100580447C true CN100580447C (en) | 2010-01-13 |
Family
ID=38999470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200710044448A Expired - Fee Related CN100580447C (en) | 2007-07-31 | 2007-07-31 | Method for determining human plasma antiviral drug concentration |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100580447C (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101949885A (en) * | 2010-08-12 | 2011-01-19 | 东南大学 | Capillary electrophoresis-electrochemiluminescence detection method for spectinomycin |
| CN104359992B (en) * | 2014-12-02 | 2016-05-04 | 湖北华世通潜龙药业有限公司 | Adopt the method for high-efficient liquid phase chromatogram technique analysis injection ACV |
| CN105866311B (en) * | 2016-05-25 | 2017-05-31 | 福建出入境检验检疫局检验检疫技术中心 | Determine the UPLC MS/MS methods of antiviral drugs residual in chicken |
| CN107543884A (en) * | 2017-08-31 | 2018-01-05 | 中国农业科学院农业质量标准与检测技术研究所 | ACV purity rubric material and preparation method and application |
| CN110702669A (en) * | 2019-09-19 | 2020-01-17 | 湖北科益药业股份有限公司 | Method for rapidly determining content of acyclovir gel |
| CN111812226A (en) * | 2020-06-01 | 2020-10-23 | 南京品生医学检验实验室有限公司 | Method for detecting concentration of antiviral drug in serum |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1619304A (en) * | 2004-09-20 | 2005-05-25 | 复旦大学 | Method of determining mycophenolic acid in human blood plasma and its metabolite |
| CN1621835A (en) * | 2004-12-16 | 2005-06-01 | 复旦大学 | A method for measuring mycophenolic acid total concentration and free concentration in human blood plasma |
| CN1804615A (en) * | 2006-01-16 | 2006-07-19 | 复旦大学附属华山医院 | Method for determining blood drug level of mizoribine |
| CN1971270A (en) * | 2005-11-24 | 2007-05-30 | 复旦大学附属华山医院 | Method for detecting blood concentration of multiple antiepileptic drugs simultaneously |
-
2007
- 2007-07-31 CN CN200710044448A patent/CN100580447C/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1619304A (en) * | 2004-09-20 | 2005-05-25 | 复旦大学 | Method of determining mycophenolic acid in human blood plasma and its metabolite |
| CN1621835A (en) * | 2004-12-16 | 2005-06-01 | 复旦大学 | A method for measuring mycophenolic acid total concentration and free concentration in human blood plasma |
| CN1971270A (en) * | 2005-11-24 | 2007-05-30 | 复旦大学附属华山医院 | Method for detecting blood concentration of multiple antiepileptic drugs simultaneously |
| CN1804615A (en) * | 2006-01-16 | 2006-07-19 | 复旦大学附属华山医院 | Method for determining blood drug level of mizoribine |
Non-Patent Citations (2)
| Title |
|---|
| HPLC法同时快速测定血浆中更昔洛韦、阿昔洛韦和喷昔洛韦的浓度. 石翠斌，白小红，姜丽芳，吴树鸣.药物分析杂志，第26卷第9期. 2006 * |
| 梯度洗脱HPLC法测定人血浆中阿昔洛韦的浓度. 李东，刘学理.药物分析杂志，第22卷第4期. 2002 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101105478A (en) | 2008-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100580447C (en) | Method for determining human plasma antiviral drug concentration | |
| CN1971270B (en) | Method for detecting blood concentration of multiple antiepileptic drugs simultaneously | |
| CN102576025A (en) | Hepatocellular carcinoma marker | |
| CN102288696A (en) | Method for measuring blood concentration of paraquat | |
| CN101093214B (en) | Method for measuring density of anti-epileptic in blood | |
| CN100580448C (en) | Method for determining human plasma phenytoin and its precursor drug and metabolite | |
| CN101393196A (en) | Method for simultaneously determining of concentration multi anesthesia medicament in blood plasma | |
| CN100414293C (en) | Method for determining blood drug level of mizoribine | |
| CN111122727A (en) | Method for simultaneously determining concentration of imatinib and imatinib metabolite in human plasma | |
| CN101226172A (en) | Method for rapidly measuring mizoribine drug concentration | |
| CN110220989A (en) | A method of detection Fasudic hydrochloride and its 9 kinds of related substances | |
| CN102269749A (en) | Method for detecting adenosine content in hericium erinaceus tablet | |
| CN111579684B (en) | Method for measuring content of total capsaicin in capsule wall material of capsule | |
| CN114487242A (en) | Characteristic spectrum of endothelium corneum Gigeriae Galli and/or vinegar endothelium corneum Gigeriae Galli and its preparation, and its construction method and content determination method | |
| CN101419224B (en) | Method for simultaneously determining mycophenolic acid ester, mycophenolic acid and metabolite thereof in human blood plasma | |
| Budikayanti et al. | Development and validation of carbamazepine plasma concentrations measurement and its application on epilepsy patients | |
| Salem et al. | Application of quantitative nuclear magnetic resonance spectroscopy for the determination of amantadine and acyclovir in plasma and pharmaceutical samples | |
| CN105675754A (en) | Method for measuring linagliptin enantiomer content by high-performance liquid chromatography | |
| CN101419225B (en) | Method for simultaneously determining mycophenolic acid ester, mycophenolic acid and metabolite thereof in human urine | |
| CN113970612B (en) | Method for measuring related substances of propiophenone tenofovir by high performance liquid chromatography | |
| CN113466360B (en) | Azilsartan 6 related substance detection method | |
| CN113960201B (en) | Method for detecting 4-dimethylaminopyridine in entecavir | |
| CN106841420A (en) | A kind of method that LC MS/MS determine Ly 7u concentration in rat plasma | |
| Saravanan | Development and Validation of RP-UPLC Method for Simultaneous Determination of Lamivudine and Dolutegravir in Combined Dosage Form | |
| CN112986469B (en) | High performance liquid chromatography analysis method for furosemide bulk drug and related substances of injection thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100113 Termination date: 20110731 |